Skip to main content
. 2014 Sep 30;30(10):988–995. doi: 10.1089/aid.2014.0181

FIG. 3.

FIG. 3.

Levels of blood biomarkers during the study. For each individual, the blood concentrations of the indicated biomarkers are plotted for values at start to end of placebo/probiotic administration (thin lines), on log10 scales. Thick lines indicate the medians for each group. Not shown are lipopolysaccharide (LPS), interleukin (IL)-1β, and IL-6 because these were not detected (<0.05 EU/ml, <7.1 pg/ml, and <0.6 pg/ml, respectively). Changes in these markers within groups were not statistically significant. Comparisons of changes between groups approached significance (p<0.2) only for soluble (s)CD163 (p=0.05). Units were μg/ml for D-dimer, mg/dl for C-reactive protein (CRP), pg/ml for IL-8, pg/ml for tumor necrosis factor (TNF)-α, ng/ml for sCD163, μg/ml for sCD14, and ng/ml for serum intestinal-type fatty acid binding protein (sI-FABP).

HHS Vulnerability Disclosure